Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novacyt | EU:ALNOV | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.003 | -0.52% | 0.576 | 0.568 | 0.58 | 0.585 | 0.568 | 0.579 | 102,560 | 16:40:00 |
From Nov 2019 to Nov 2024
By Sabela Ojea
Novacyt SA said Thursday that it continues to work with its legal advisers to progress the U.K. Department of Health and Social Care's dispute over a supply contract.
In April the clinical-diagnostics specialist, which is listed in France and the U.K., said the parties haven't reached an agreement to extend the contract for the supply of Covid-19 diagnostic kits and other products.
The London-listed company also said that the accounting treatment of the DHSC revenue and costs in the first half doesn't change its legal position or rights in relation to the dispute.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 16, 2021 04:33 ET (08:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novacyt Chart |
1 Month Novacyt Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
